Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (812 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
An umbrella term used to describe a pattern of disabilities and abnormalities that result from fetal exposure to ethanol during pregnancy. It encompasses a phenotypic range that can vary greatly between individuals, but reliably includes one or more of the following: characteristic facial dysmorphism, fetal growth retardation, central nervous system abnormalities, cognitive and/or behavioral dysfunction, birth defects. The level of maternal alcohol consumption does not necessarily correlate directly with disease severity.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: FASD; FASDs; Fetal Alcohol Spectrum Disorder; Fetal Alcohol Syndrome; Syndrome, Fetal Alcohol; Alcohol Related Neurodevelopmental Disorder; FAE (Fetal Alcohol Effects); FAEs (Fetal Alcohol Effects).
Where it fits in the MeSH classification
- Broader topics
- Fetal Diseases; Alcohol-Induced Disorders
- See also
- Alcoholism
Related concepts
- Ethanol
- Fetal Growth Retardation
- Birth Defects
Research landscape
PubMed indexes 5,063 records tagged with the MeSH heading “Fetal Alcohol Spectrum Disorders” (counts retrieved 2026-11-04). 859 of them (17.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,876 records.
Reviews account for 950 records (18.8%) and meta-analyses for 33. Randomized controlled trials number 58 (1.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1,876 |
| 2000-2009 | 894 |
| 2010-2019 | 1,434 |
| 2020 onward | 859 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 950 | 18.8% |
| Meta-analyses | 33 | 0.7% |
| Randomized controlled trials | 58 | 1.1% |
Method: PubMed query "Fetal Alcohol Spectrum Disorders"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.
Reading the evidence in kidney, urology and women's health
Kidney, urinary and reproductive health research uses lab markers (such as creatinine), imaging, symptom scores and registry data on pregnancy and birth. Findings about pregnancy are especially sensitive to who was studied and when in pregnancy exposure occurred. Nothing on this page is advice about treatment, fertility or pregnancy; speak to a qualified clinician. Check the population, the outcome measured and whether the study accounted for other health differences between groups.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Alcohol's Impact on the Fetus | 2021 | Review article Design not recorded in structured metadata | 61 | cc by PMID 34684453 · DOI · PMC8541151 |
| Infant circulating MicroRNAs as biomarkers of effect in fetal alcohol spectrum disorders | 2021 | Clinical trial Design not recorded in structured metadata | 38 | cc by PMID 33446819 · DOI · PMC7809131 |
| Prenatal and Postnatal Choline Supplementation in Fetal Alcohol Spectrum Disorder | 2022 | Review article Design not recorded in structured metadata | 35 | cc by PMID 35277047 · DOI · PMC8837993 |
| Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disorders | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 41484421 · DOI · PMC12864738 |
Alcohol's Impact on the Fetus [1]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundAlcohol is a teratogen and prenatal exposure may adversely impact the developing fetus, increasing risk for negative outcomes, including Fetal Alcohol Spectrum Disorder (FASD).
- Closing excerpt
- Prevention of prenatal alcohol exposure and early identification of affected individuals should be a global public health priority.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (158 words)
BackgroundAlcohol is a teratogen and prenatal exposure may adversely impact the developing fetus, increasing risk for negative outcomes, including Fetal Alcohol Spectrum Disorder (FASD). Global trends of increasing alcohol use among women of childbearing age due to economic development, changing gender roles, increased availability of alcohol, peer pressure and social acceptability of women's alcohol use may put an increasing number of pregnancies at risk for prenatal alcohol exposure (PAE). This risk has been exacerbated by the ongoing COVID-19 pandemic in some countries.MethodThis literature review presents an overview on the epidemiology of alcohol use among childbearing age and pregnant women and FASD by World Health Organization regions; impact of PAE on fetal health, including FASD; associated comorbidities; and social outcomes.Results/conclusionThe impact of alcohol on fetal health and social outcomes later in life is enormous, placing a huge economic burden on countries. Prevention of prenatal alcohol exposure and early identification of affected individuals should be a global public health priority.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34684453 · DOI · PMC8541151
Infant circulating MicroRNAs as biomarkers of effect in fetal alcohol spectrum disorders [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Prenatal alcohol exposure (PAE) can result in cognitive and behavioral disabilities and growth deficits.
- Closing excerpt
- These findings indicate that infant exmiRNAs can help identify infants who will exhibit PAE-related deficits in growth and cognition.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (249 words)
Prenatal alcohol exposure (PAE) can result in cognitive and behavioral disabilities and growth deficits. Because alcohol-related neurobehavioral deficits may occur in the absence of overt dysmorphic features or growth deficits, there is a need to identify biomarkers of PAE that can predict neurobehavioral impairment. In this study, we assessed infant plasma extracellular, circulating miRNAs (exmiRNAs) obtained from a heavily exposed Cape Town cohort to determine whether these can be used to predict PAE-related growth restriction and cognitive impairment. PAE, controlling for smoking as a covariate, altered 27% of expressed exmiRNAs with clinically-relevant effect sizes (Cohen's d ≥ 0.4). Moreover, at 2 weeks, PAE increased correlated expression of exmiRNAs across chromosomes, suggesting potential co-regulation. In confirmatory factor analysis, the variance in expression for PAE-altered exmiRNAs at 2 weeks and 6.5 months was best described by three-factor models. Pathway analysis found that factors at 2 weeks were associated with (F1) cell maturation, cell cycle inhibition, and somatic growth, (F2) cell survival, apoptosis, cardiac development, and metabolism, and (F3) cell proliferation, skeletal development, hematopoiesis, and inflammation, and at 6.5 months with (F1) neurodevelopment, neural crest/mesoderm-derivative development and growth, (F2) immune system and inflammation, and (F3) somatic growth and cardiovascular development. Factors F3 at 2 weeks and F2 at 6.5 months partially mediated PAE-induced growth deficits, and factor F3 at 2 weeks partially mediated effects of PAE on infant recognition memory at 6.5 months. These findings indicate that infant exmiRNAs can help identify infants who will exhibit PAE-related deficits in growth and cognition.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33446819 · DOI · PMC7809131
Prenatal and Postnatal Choline Supplementation in Fetal Alcohol Spectrum Disorder [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Fetal alcohol spectrum disorder (FASD) is common and represents a significant public health burden, yet very few interventions have been tested in FASD.
- Closing excerpt
- Lastly, we conclude with a review of practical considerations in choline supplementation, including dose, formulation, and feasibility in children.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)
Fetal alcohol spectrum disorder (FASD) is common and represents a significant public health burden, yet very few interventions have been tested in FASD. Cognitive deficits are core features of FASD, ranging from broad intellectual impairment to selective problems in attention, executive functioning, memory, visual-perceptual/motor skills, social cognition, and academics. One potential intervention for the cognitive impairments associated with FASD is the essential nutrient choline, which is known to have numerous direct effects on brain and cognition in both typical and atypical development. We provide a summary of the literature supporting the use of choline as a neurodevelopmental intervention in those affected by prenatal alcohol. We first discuss how alcohol interferes with normal brain development. We then provide a comprehensive overview of the nutrient choline and discuss its role in typical brain development and its application in the optimization of brain development following early insult. Next, we review the preclinical literature that provides evidence of choline's potential as an intervention following alcohol exposure. Then, we review a handful of existing human studies of choline supplementation in FASD. Lastly, we conclude with a review of practical considerations in choline supplementation, including dose, formulation, and feasibility in children.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35277047 · DOI · PMC8837993
Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disorders [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Prenatal alcohol exposure impacts fetal development, leading to Fetal Alcohol Spectrum Disorders (FASD) characterized by cognitive, behavioral, and physical impairments.
- Closing excerpt
- gov identifier: NCT02558933 (registered 22 September 2015).
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (210 words)
Prenatal alcohol exposure impacts fetal development, leading to Fetal Alcohol Spectrum Disorders (FASD) characterized by cognitive, behavioral, and physical impairments. This pre-post, open-label, non-randomized pilot study explores Epigallocatechin-3-Gallate (EGCG), a potent antioxidant and neuronal plasticity modulator, as a therapeutic intervention for FASD improvement. In a 12-month pilot study, patients with 40 FASD (mean age 10 ± 3 years) received 9 mg/kg/day of EGCG, with outcomes assessed through RNA sequencing and neurocognitive evaluations (WISC-IV, CBCL 6-18, and NEPSY-II). Reduced levels of oxidative stress were observed after 6 and 12 months of treatment with EGCG. Significant neurocognitive improvements were shown after one year of treatment in Perceptual Reasoning Index (PRI) and Working Memory Index (WMI) using the WISC-IV test. CBCL test revealed an improvement in aggressive behavior scores after EGCG treatment. NEPSY-II assessment showed improvements in face memory and delayed face memory. Interestingly, no significant improvements were observed in intelligence quotient, attention, anxiety, or depression, which affect a proportion of individuals diagnosed with FASD. Additionally, EGCG modulates molecular pathways associated with neuroinflammation, immune response, and neurogenesis. This study highlights EGCG as a potential therapeutic candidate to ameliorate cognitive and behavioral deficits in children affected by FASD, revealing potential pathways and biomarkers that contribute to these improvements.ClinicalTrials.gov identifier: NCT02558933 (registered 22 September 2015).
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41484421 · DOI · PMC12864738
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis [5]
- Research article Updated Clinical Guidelines for Diagnosing Fetal Alcohol Spectrum Disorders [6]
- Research article Fetal alcohol spectrum disorders: an overview [7]
- Research article Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth: A Systematic Review and Meta-analysis [8]
- Research article Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior [9]
- Research article Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan [10]
Full-text reviews on EvidenceLib
Open-access review articles about this topic, reproduced in full with authors, licence and references.
Comparing rates of agreement between different diagnostic criteria for fetal alcohol spectrum disorder: A systematic review
Graysen Myers, Michael Burd, Marilyn G. Klug et al. · Alcohol, Clinical & Experimental Research 2024 · CC BY 4.0
References
- Popova S, Dozet D, Shield K, Rehm J, Burd L. Alcohol's Impact on the Fetus. . 2021. PMID 34684453 · DOI · PMC8541151
- Mahnke AH, Sideridis GD, Salem NA, Tseng AM, Carter RC, Dodge NC, et al.. Infant circulating MicroRNAs as biomarkers of effect in fetal alcohol spectrum disorders. . 2021. PMID 33446819 · DOI · PMC7809131
- Ernst AM, Gimbel BA, de Water E, Eckerle JK, Radke JP, Georgieff MK, et al.. Prenatal and Postnatal Choline Supplementation in Fetal Alcohol Spectrum Disorder. . 2022. PMID 35277047 · DOI · PMC8837993
- Ramos-Triguero A, Astals-Vizcaino M, Navarro-Tapia E, Vieiros M, Bastons-Compta A, Martínez L, et al.. Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disorders. . 2026. PMID 41484421 · DOI · PMC12864738
- Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. Lancet Glob Health. 2017. PMID 28089487 · DOI
- Hoyme HE, Kalberg WO, Elliott AJ, Blankenship J, Buckley D, Marais AS, et al.. Updated Clinical Guidelines for Diagnosing Fetal Alcohol Spectrum Disorders. Pediatrics. 2016. PMID 27464676 · DOI · PMC4960726
- Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol Rev. 2011. PMID 21499711 · DOI · PMC3779274
- Lange S, Probst C, Gmel G, Rehm J, Burd L, Popova S. Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017. PMID 28828483 · DOI · PMC5710622
- Riley EP, McGee CL. Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. Exp Biol Med (Maywood). 2005. PMID 15956765 · DOI
- Cook JL, Green CR, Lilley CM, Anderson SM, Baldwin ME, Chudley AE, et al.. Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. CMAJ. 2016. PMID 26668194 · DOI · PMC4754181
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-11-04.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.